Singapore markets closed

Clovis Oncology, Inc. (CLVS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.3150+0.1250 (+2.98%)
As of 11:52AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close4.1900
Open4.2000
Bid4.2800 x 2900
Ask4.2900 x 1400
Day's range4.1700 - 4.3250
52-week range4.0600 - 11.1000
Volume1,061,403
Avg. volume2,891,767
Market cap510.939M
Beta (5Y monthly)1.76
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition

    Clovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.

  • Motley Fool

    Can These Former Biotech Growth Stocks Regain Their Form?

    All that being said, biotech stocks in the middle of an important commercial launch or long-winded clinical trial can be powerful growth vehicles. Acadia Pharmaceuticals (NASDAQ: ACAD) and Clovis Oncology (NASDAQ: CLVS) have both lagged behind the broader markets in a big way in 2021, even though they were super-charged growth stocks in the not-so-distant past. While there's no guarantee that either of these names will regain its prior form as a top growth stock, these two biotech companies do sport the type of key assets to spark a comeback.

  • Zacks

    Clovis (CLVS) Down 3.2% Since Last Earnings Report: Can It Rebound?

    Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.